NOVAVAX INC (NVAX)
Health Care · Vaccine manufacturers / therapeutic development · NASDAQ
Novavax is a biotechnology company developing vaccine candidates and adjuvant technology to address infectious diseases and other medical needs through its proprietary protein-based nanoparticle platform.
What NOVAVAX INC does
Novavax, Inc. is a biotechnology company that develops vaccines for infectious diseases using its proprietary recombinant protein-based nanoparticle technology and its Matrix-M™ adjuvant. The company's technology platform aims to create potent, durable, and broad immune responses, including antigen-sparing capabilities. Novavax commercializes its products through its own vaccine portfolio, such as the Nuvaxovid COVID-19 vaccine, and through partnerships that utilize its Matrix-M adjuvant for third-party vaccines.
Themes: vaccine platform technology, COVID-19 vaccines, malaria vaccines, vaccine adjuvants, partnerships / licensing revenue
Fundamentals
- Price$8.94 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- 1-year return+17.2% 2025-08-21 close $7.63 → 2026-08-21 close $8.94
- P/E2.98 as of 2026-08-24
- Net margin-59.9% as of 2026-08-24
- Gross margin+79.2% as of 2026-08-24
- ROE+283.1% as of 2026-08-24
- Debt / equity6.07 as of 2026-08-24
- Revenue growth (YoY)-61.6% as of 2026-08-24
- Revenue CAGR (3y)-17.2% SEC XBRL
- Beta2.54 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How NVAX compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NOVAVAX INC looks technically
NOVAVAX INC (NVAX) is trading 6.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 135 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-07-10, pushing above its recent trading range. It is 25.3% below its highest point of the past year. Trading volume is running unusually high — about 3.0× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 6.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.46 | $8.46 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.43 | $8.43 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 135 trading days ago — a "golden cross", a bullish long-term signal | 135 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 6.0% above | +6.0% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($7.46 to $9.20) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 85.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.97 | $11.97 |
|---|---|---|
| From the 52-week high | it is 25.3% below its 52-week high (its highest price of the past year) | -25.3% |
| Above the 52-week low | it is 44.2% above its 52-week low (its lowest price of the past year) | +44.2% |
| Below the 52-week high | it is 25.3% below its highest point of the past year | 25.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-10, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $331.68 (set on 2021-02-09) | $331.68 |
| Given back of the 52-week move | over the past year its closes ranged ($6.22 to $11.19), and it has given back around half of its rise from last year’s low — 45% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.96 to $8.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 45.3% |
| From the all-time high | it is 97.3% below its all-time high | -97.3% |
| Nearest price level | it is trading 1.3% below a resistance level at $9.05 — a price it turned at three times since 2025-09-22, most recently on 2026-04-17. Since 2024-08-21 it has 11 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $3.53 (set on 2024-02-05) | $3.53 |
| Above the all-time low | it is 153.1% above its all-time low | +153.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 36th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4222 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4222 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.99 and $8.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.99 – $7.88 – $8.76 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (6.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.0× its 30-day average, a sign of heightened interest | 3.03× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Open gap | it gapped 6.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 7.93 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.3% |
| Gap filled | a 3.6% gap down opened on 2026-08-20 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.4 percentage points (the stock gained 10.7% while the market gained 2.3%) | +8.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.5 percentage points (the stock lost 0.4% while the market gained 3.1%) | -3.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.9 percentage points (the stock lost 2.8% while the market gained 11.1%) | -13.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 3.3 percentage points (the stock gained 17.2% while the market gained 20.5%) | -3.3% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.0% of the share price. | -1.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.08 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -1.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $8.35 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +7.1% |
Price levels it has turned at before
NVAX last closed at $8.94 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.05 | Resistance | 1.3% above the last close | turned there three times · 2025-09-22 to 2026-04-17 |
| $8.63 | Support | 3.4% below the last close | turned there twice · 2025-03-03 to 2026-05-19 |
| $8.47 | Support | 5.2% below the last close | turned there three times · 2025-03-14 to 2026-06-11 |
| $9.55 | Resistance | 6.9% above the last close | turned there three times · 2024-10-16 to 2024-12-06 |
| $8.31 | Support | 7.1% below the last close | turned there twice · 2025-01-16 to 2026-06-25 |
| $9.78 | Resistance | 9.3% above the last close | turned there twice · 2024-12-16 to 2025-01-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$14.00 range $7.00 – $25.00; median $16.02
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NVAX
- Consensus EPS estimate-$0.4 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Severe revenue decline (-52.48% YoY) driven by precipitous drop in COVID-19 vaccine sales ($621.7M in Q1 2025 to $42.2M in Q1 2026), reflecting market saturation and competitive pressure","Negative operating margins and accumulated deficit (-$4.58B as of March 2026); company is unprofitable and burning cash as it transitions to partnership/licensing model","Heavy dependence on licensing and partnerships (which generated $97.3M in Q1 2026 versus product sales of $42.2M) creates revenue concentration risk if key partnerships (Sanofi, Pfizer, Serum Institute of India) underperform or terminate"]
What changed in the latest 10-Q
AI-assisted comparison of NVAX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'Nuvaxovid™' and 'JN.1 COVID-19 Vaccine' as specific vaccine formulations (newer filing, 2026-05-06)
- Reference to 'Nuvaxovid™ COVID-19 Vaccine for the 2025-2026 vaccination season' (newer filing, 2026-05-06)
- Mention of 'Pfizer License Agreement' as source of potential royalties and milestones (newer filing, 2026-05-06)
- Statement about 'our research and development investment strategy' as separate forward-looking item (newer filing, 2026-05-06)
- Reference to 'the potential expansion of our pipeline beyond infectious diseases into other therapeutic areas' (newer filing, 2026-05-06)
- Explicit reference to 'our CIC vaccine candidate and our stand-alone influenza vaccine candidate' as separate from development discussions (newer filing, 2026-05-06)
- Removed:
- Reference to 'our strategic priorities' as forward-looking statement element (older filing, 2025-11-06)
- Reference to 'our early-stage pipeline' as part of corporate growth strategy (older filing, 2025-11-06)
- Specific vaccine formulation names 'NVX-CoV2373' (prototype), 'NVX-CoV2601' (2023-2024), and 'NVX-CoV2705' (2024-2025) (older filing, 2025-11-06)
- Phrase 'one year from the date of our unaudited financial statements for the period ended September 30, 2025 are issued' regarding going concern period (older filing, 2025-11-06)
- Reference to 'anticipated timing of the U.S. FDA's approval of our BLA supplement to extend the shelf life of our COVID-19 vaccine' (older filing, 2025-11-06)
- Reference to 'COVID-19 variant strain-containing monovalent or bivalent formulations' (older filing, 2025-11-06)
- Phrase 'our plans regarding APA amendments' changed to 'plans regarding APA amendments' (older filing, 2025-11-06)
- Reference to 'our other license agreements' as source of royalties and milestones (older filing, 2025-11-06)
- Reworded:
- Going concern statement changed from 'through one year from the date of our unaudited financial statements for the period ended September 30, 2025 are issued' to 'through the next 12 months from the issuance of the financial statements included in this Quarterly Report on Form 10-Q' (reflects updated filing period to March 31, 2026)
- COVID-19 Vaccine references changed from 'COVID-19 Program' terminology to more direct 'COVID-19 Vaccine' naming convention
- 'Sanofi Pasteur Inc. ("Sanofi")' reference removed; 'Sanofi CLA' retained but without company name definition in this section
- Changed 'our research and development ("R&D") investment strategy and key value drivers' to separate items listing 'our corporate growth strategy and key value drivers' and later 'our research and development investment strategy'
- Removed specific reference to 'BLA supplement' for shelf life extension approval timing
- Phrase restructured from 'our other license agreements' to explicitly mention 'Pfizer License Agreement' by name
- Notes:
- Text appears truncated at end of both versions; comparison based on available content
- Newer filing reflects Q1 2026 period (ended March 31, 2026) while older filing reflects Q3 2025 period (ended September 30, 2025), accounting for some naturally updated references
- Some changes reflect updated vaccine season references (2025-2026 vs. 2024-2025 vs. 2023-2024)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for NVAX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NVAX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 24,733,483
- Reported value $201,330,555
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NVAX had 45,659,491 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NVAX had 27.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 16.63 days to cover at the same settlement.
- Reported short interest (shares) 45,659,491
- Short interest (% of shares outstanding) 27.7%
- Prior settlement (shares) 43,821,227
- Reported change 4.19%
- Days to cover (reported) 16.63
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Moderna (MRNA)
- GSK (GSK)
- AstraZeneca (AZN)
- Sanofi (SNY)
- BioNTech (BNTX)
- Merck & Co. (MRK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVAX vs…
NVAX ranks in…
Frequently asked questions
What does NOVAVAX INC (NVAX) do?
Novavax, Inc. is a biotechnology company that develops vaccines for infectious diseases using its proprietary recombinant protein-based nanoparticle technology and its Matrix-M™ adjuvant. The company's technology platform aims to create potent, durable, and broad immune responses, including antigen-sparing capabilities.
What sector is NOVAVAX INC (NVAX) in?
NOVAVAX INC (NVAX) is classified in the Health Care sector. Its industry is Vaccine manufacturers / therapeutic development. It trades on NASDAQ.
Who are NOVAVAX INC's (NVAX) competitors?
Notable peers of NOVAVAX INC (NVAX) include Pfizer, Moderna, GSK, AstraZeneca and Sanofi. This peer set is informational only — not financial advice.
Is NOVAVAX INC (NVAX) overbought or oversold right now?
NOVAVAX INC (NVAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVAX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.